Experienced in Small Lymphocytic Lymphoma (SLL)

Dr. John M. Wallmark

Hematology Oncology
Johns Hopkins Medicine
Maryland Oncology Hematology PA
Rockville, MD 
Offers Telehealth

Experienced in Small Lymphocytic Lymphoma (SLL)
Johns Hopkins Medicine
Maryland Oncology Hematology PA
Rockville, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Wallmark is a Hematologist Oncology provider in Rockville, Maryland. Dr. Wallmark is rated as an Experienced provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Multiple Myeloma, and Colorectal Cancer.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
UNC Medical Center, Internal Medicine, 1995
Specialties
Hematology Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Hospital of the University of Pennsylvania, Hematology and Oncology, 1998
Hospital Affiliations
Suburban Hospital
Holy Cross Germantown Hospital
Adventist Healthcare Shady Grove Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Maryland Oncology Hematology PA
Shady Grove Medical Building Suite200, Suite 200, Rockville, MD 20850
Call: 301-424-6231

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: SEA-TGT, Pembrolizumab
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

4 Total Publications

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 12, 2018
View All 4 Publications
Similar Doctors
Elite in Small Lymphocytic Lymphoma (SLL)
Dr. Bruce D. Cheson
Hematology | Hematology Oncology | Oncology
Elite in Small Lymphocytic Lymphoma (SLL)
Dr. Bruce D. Cheson
Hematology | Hematology Oncology | Oncology

American Oncology Partners PA

6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
 (18.8 miles away)
301-571-0019
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Cheson is a Hematologist and a Hematologist Oncology provider in Bethesda, Maryland. Dr. Cheson is rated as an Elite provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Cheson is currently accepting new patients.

Lode Swinnen
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Lode Swinnen
Oncology | Hematology | Hematology Oncology
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Lode Swinnen
Oncology | Hematology | Hematology Oncology

Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD 
 (15.4 miles away)
410-955-8964
Languages Spoken:
English, Dutch, French
See accepted insurances

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Bruce R. Kressel
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Bruce R. Kressel
Hematology Oncology | Oncology
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Bruce R. Kressel
Hematology Oncology | Oncology

Sibley Memorial Hospital

5255 Loughboro Road Northwest, Building B, Building B, 
Washington, DC 
 (22.1 miles away)
202-660-6500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce R. Kressel, M.D., is a medical oncologist at Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital and an instructor at Johns Hopkins University School of Medicine. In addition to an expertise in breast and lung cancer, Dr. Kressel has an expertise in gynecologic oncology and general medical oncology, with specific focuses on hematologic malignancies including lymphoma, leukemia and myeloma. Dr. Kressel earned his medical degree at Tufts University School of Medicine. He completed a residency in internal medicine at George Washington University School of Medicine, followed by a fellowship in hematology and oncology, also at George Washington University School of Medicine. Dr. Kressel completed a fellowship in oncology at the Georgetown Lombardi Comprehensive Cancer Center as well. Dr. Kressel has been regularly named one of America’s Top Doctors and one of America's Top Doctors for Cancer by Castle Connolly. He has also been named a Top Doctor in the Washington D.C. and Washington-Baltimore areas by Castle Connolly, as well as a Top Doctor by Consumers’ Checkbook Magazine and Washingtonian Magazine. Dr. Kressel is a member of the American Society of Clinical Oncology and the American Society of Hematology. Dr. Kressel has contributed to numerous publications, presentations and clinical trials. Dr. Kressel is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Essential Thrombocythemia, Non-Hodgkin Lymphoma, Gastric Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Splenectomy.

VIEW MORE SMALL LYMPHOCYTIC LYMPHOMA (SLL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wallmark's expertise for a condition
ConditionClose
    • Distinguished
    • Breast Cancer
      Dr. Wallmark is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Multiple Myeloma
      Dr. Wallmark is
      Distinguished
      . Learn about Multiple Myeloma.
      See more Multiple Myeloma experts
    • Paget Disease of the Breast
      Dr. Wallmark is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Adult Immune Thrombocytopenia
      Dr. Wallmark is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Agranulocytosis
      Dr. Wallmark is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anemia
      Dr. Wallmark is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Angiosarcoma
      Dr. Wallmark is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Childhood Iron Deficiency Anemia
      Dr. Wallmark is
      Advanced
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Wallmark is
      Advanced
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    View All 44 Advanced Conditions
    • Experienced
    • Acquired Hemophilia
      Dr. Wallmark is
      Experienced
      . Learn about Acquired Hemophilia.
      See more Acquired Hemophilia experts
    • Acute Mountain Sickness
      Dr. Wallmark is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Adult Soft Tissue Sarcoma
      Dr. Wallmark is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Wallmark is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Wallmark is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Antiphospholipid Syndrome
      Dr. Wallmark is
      Experienced
      . Learn about Antiphospholipid Syndrome.
      See more Antiphospholipid Syndrome experts
    View All 149 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.